DISEASE PROGRESSION IN STAGE A PROSTATE CANCER

To study the disease progression in stage A prostate cancer, 212 patients with stage A from a group of 3370 patients who underwent transurethral resection of the prostate, or subcapsular prostatectomy during the period 1972–1991 were followed. The stage A cases were subdivided into 103 A1 patients and 109 A2 patients and their subsequent course was followed for an average of 41.7 months (6–174 months). Progression to clinical cancer was found in 12 patients, 2 from A1 and 10 from A2 groups. This progression was evident 40.5 months (14–130 months) after prostatectomy. Eight (67%) of these cases responded to endocrine therapy. The rate of expression of ras p21, and the number of argyrophilic nucleolar organizer regions in stage A cancer cells were greater in progressing than in non‐progressing cases. These results indicate that stage A cancer with progression arises mainly from the A2 subgroup and exhibits a distinctly proliferative potential even at small foci.

[1]  T. Igarashi,et al.  State of Adenomatous Polyposis Coli Gene and ras Oncogenes in Japanese Prostate Cancer , 1994, Japanese journal of cancer research : Gann.

[2]  S. Broder.  Perspectives on Cancer in Japan and the United States' , 1993, Japanese journal of cancer research : Gann.

[3]  J. Ward,et al.  K‐ras activation and ras p21 expression in latent prostatic carcinoma in Japanese men , 1992, Cancer.

[4]  T. Stamey,et al.  The predictive significance of substaging stage A prostate cancer (A1 versus A2) for volume and grade of total cancer in the prostate. , 1992, The Journal of urology.

[5]  R. deVere White,et al.  Activated ras alleles in human carcinoma of the prostate are rare. , 1991, Cancer research.

[6]  N. Weidner,et al.  Nucleolar Organizer Regions (NOR) in Hyperplastic and Neoplastic Prostate Disease , 1990, The American journal of surgical pathology.

[7]  W. Isaacs,et al.  ras gene mutations in human prostate cancer. , 1990, Cancer research.

[8]  T. Stamey,et al.  Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate , 1990, Cancer.

[9]  J. L. Bos,et al.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[10]  D. Treré,et al.  The silver-stained proteins of interphasic nucleolar organizer regions as a parameter of cell duplication rate. , 1989, Experimental cell research.

[11]  I. Thompson,et al.  Extended follow-up of stage A1 carcinoma of prostate. , 1989, Urology.

[12]  J. Isaacs,et al.  Expression of a transfected v-Harvey-ras oncogene in a Dunning rat prostate adenocarcinoma and the development of high metastatic ability. , 1988, The Journal of urology.

[13]  J. Oesterling,et al.  Tumor volume versus percentage of specimen involved by tumor correlated with progression in stage A prostatic cancer. , 1988, The Journal of urology.

[14]  P. Walsh,et al.  Prognosis of untreated stage A1 prostatic carcinoma: a study of 94 cases with extended followup. , 1986, The Journal of urology.

[15]  M. Blute,et al.  Long-term followup of young patients with stage A adenocarcinoma of the prostate. , 1986, The Journal of urology.

[16]  H. Ozen,et al.  Incidental carcinoma of the prostate: factors influencing prognosis. , 1986, British journal of urology.

[17]  B. Lawshe,et al.  Diagnosis of Adenocarcinoma in Transurethral Resectates of the Prostate Gland , 1986, The American journal of surgical pathology.

[18]  G. Stemmermann,et al.  Geographic pathology of latent prostatic carcinoma , 1982, International journal of cancer.

[19]  P. Walsh,et al.  Pathological factors that influence prognosis in stage A prostatic cancer: the influence of extent versus grade. , 1981, The Journal of urology.

[20]  G. Stemmerman,et al.  Comparative study of latent carcinoma of the prostate among Japanese in Japan and Hawaii. , 1973, Journal of the National Cancer Institute.

[21]  M. Masai,et al.  Argyrophilic nucleolar organizer regions in benign hyperplastic and cancerous human prostates , 1992, The Prostate.

[22]  J W Moul,et al.  Infrequent RAS oncogene mutations in human prostate cancer , 1992, The Prostate.

[23]  M. Masai,et al.  Histochemical examination of expression of ras p21 protein and R 1881-binding protein in human prostatic cancers. , 1990, European journal of cancer.

[24]  T. Stamey,et al.  Stage A versus stage B adenocarcinoma of the prostate: morphological comparison and biological significance. , 1988, The Journal of urology.

[25]  O. Alfthan,et al.  T0 carcinoma of the prostate: influence of tumor extent and histologic grade on prognosis of untreated patients. , 1986, European urology.